Navigation Links
Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
Date:10/30/2008

transplantation in the United States. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the United States die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the United States are under treatment today. Most infected individuals are unaware of their infection status and the large majority of individuals who know their condition do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combinations of two or more direct antivirals. It is expected that the next generation of therapies for treatment of HCV will include small molecules, such as ANA598, that directly act upon specific viral enzymes to inhibit viral replication and orally administered agents such as ANA773, which are being developed to potentially replace injectable interferon. These new therapies are expected to improve overall therapy by increasing cure rates and potentially improving tolerability and convenience of treatment if doses of currently used agents can be reduced or eliminated.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents: ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cance
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... MediVet America and NanoFiber Veterinary ... at the specialized Wolvega Horse Clinic. , Due to ... was ruptured 90% and her deep digital flexor tendon ... sentence for a horse. , The clinic has performed ... This revolutionary regenerative option for ruptured tendons has ...
(Date:9/19/2014)... simple. From crop yields to disease risks, the biological ... "complex traits." Just as for heightthe textbook example of ... disease are shaped by multiple genetic and environmental influences, ... track down such genes, geneticists typically mate two individuals ... and a small mouseand then study their descendents, looking ...
(Date:9/19/2014)... to move data would consume much less power ... as chips, transistor counts rise. , Of the ... emitters, modulators, and detectors emitters are the ... optical chips is molybdenum disulfide (MoS2), which has ... atom-thick layer. Other experimental on-chip light emitters have ...
(Date:9/19/2014)... 19, 2014  An entire month is dedicated to ... – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease ... muscle atrophy, weakness, and foot and hand deformities. CMT ... worldwide. CMT is a progressive disease, and over time ... mobility devices such as leg braces, wheelchairs and scooters ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Want to link genes to complex traits? Start with more diversity 2Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2
... from Nicusa Capital urging BioClinica (Nasdaq: BIOC ) shareholders ... Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy: ... the Board BioClinica, Inc. 826 Newtown-Yardley Rd. Newtown, PA  18940 ... As of May 4, 2011, Nicusa owns 854,119 shares, ...
... Mass., May 4, 2011 InVivo Therapeutics (OTCBB: ... groundbreaking technologies for the treatment of spinal cord ... School of Medicine,s Miami Project to Cure Paralysis, ... today announced a strategic research collaboration for the ...
... , COLLEGE PARK, Md. It took nearly a decade ... their work identifying the anthrax strain used in the 2001 ... members of the high-powered science team have published the first ... of "microbial forensics" and gave bioterrorism investigators a way to ...
Cached Biology Technology:This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 2This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 3This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 4This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 5InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries 2InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries 3InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries 4Now, the story can be told how scientists helped ID 'Amerithrax' 2Now, the story can be told how scientists helped ID 'Amerithrax' 3
(Date:9/21/2014)... dioxide emissions, the main contributor to global warming, are set ... of 40 billion tonnes. , The 2.5 per cent projected ... Carbon Project, which is co-led in the UK by researchers ... University of East Anglia and the College of Engineering, Mathematics ... comes ahead of the New York Climate Summit, where world ...
(Date:9/21/2014)... In recent years, new strains of bacteria have emerged ... these superbugs, including drug-resistant forms of tuberculosis and staphylococcus, ... at least 23,000. Despite the urgent need for new ... antibiotics in the past decade. , MIT engineers have ... Using a gene-editing system that can disable any target ...
(Date:9/21/2014)... MA -- Shellfish such as mussels and barnacles secrete ... or ship hulls, even underwater. Inspired by these natural ... materials that could be used to repair ships or ... their new waterproof adhesives, the MIT researchers engineered bacteria ... mussel proteins as well as a bacterial protein found ...
Breaking Biology News(10 mins):CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3Battling superbugs 2Battling superbugs 3Battling superbugs 4Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3
... Men with type 1 diabetes may be able ... tissue, say Georgetown University Medical Center (GUMC) researchers who ... Cell Biology 50th annual meeting in Philadelphia. Their laboratory ... human spermatogonial stem cells (SSCs) extracted from testicular tissue ...
... ANTONIO Do not delay treatment of breast cancer just ... Dr. med, of the German Breast Group. This suggestion ... treatment options on the infant. Loibl presented this data at ... Dec. 8-12, 2010. "At the time we started the ...
... the trail of some of the most economically damaging organisms ... water fungus that causes powdery mildew and the water molds ... mildew in cruciferous vegetables and other crops. , "We have ... Professor Sophien Kamoun, head of the Sainsbury Laboratory on the ...
Cached Biology News:'Grow your own transplant' may be possible for men with type 1 diabetes 2Unique needs and outcomes of pregnant women with breast cancer identified 2Gene hunters tackle crop diseases 2
... Ambions 96 well Magnetic-Ring Stand is ... 96 well U-bottom microplates. The stand has ... 96 well microtiter plate footprint. The use ... enables fast and easy magnetic separation. With ...
... from Thermus aquaticus expressed in E. coli; ... of 250 units enzyme/tube and Buffer I ... the same enzyme as AmpliTaq DNA Polymerase ... separation process to ensure that contaminating bacterial ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
... is a versatile and easy-to use enzyme, ... GCpro Taq DNA Polymerase is prepared from ... containing the DNA polymerase I gene from ... processive 5'-3' DNA polymerase activity. Its inherent ...
Biology Products: